Sensus Healthcare, Inc.

Good day and welcome to the Census Healthcare Second Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one, on a touchtone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Tirth Patel with Alliance Advisors IR. Please go ahead.

Good afternoon. This is Tirth Patel with Alliance Advisors IR. I'd like to start by apologizing for the press release being issued later than usual, as there was a system-wide glitch with our wire service. But thank you all for joining today's call to discuss Census Healthcare Second Quarter 2025 Financial Results. Joining me from Census are Joe Sardano, Chairman and Chief Executive Officer, Michael Sardano, President and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Census Healthcare assumes, plans, expects, believes, intends, or anticipates, and other similar expressions that will, should, or may occur in the future are forward-looking statements. The forward-looking statements are management's beliefs based upon currently available information as of the date of this conference call, August 7th, 2025. Census Healthcare undertakes no obligation to revise or update any forward-looking statements except as required by law. All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K, 10-Q, and other SEC filings. During today's call, references will be made to certain non-GAAP financial measures. Census believes these measures provide useful information for investors, yet they should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's financial results news release. With that, I'd like to turn the call over to Joe Cerdano.

Joe? Thank you, Terz. Good afternoon, everyone, and thank you for joining us. As you can see from the financial results we're reporting today, after a very dynamic start to Q2, our second quarter domestic sales momentum was temporarily stalled by proposed local coverage determination, or LCD, that would limit the reimbursement of ultrasound when used with our SRT100 vision systems. Also, just a few weeks ago, Medicare stepped in with a proposed physician fee schedule that we believe may fundamentally alter demand for our products. Let me explain, starting with the LCD. Our SRT100 vision combines the treatment power of superficial radiotherapy with image-guided ultrasound to ensure the best possible clinical outcome for patients. When treating non-melanoma skin cancer, it's the only way for a physician and patient to establish a treatment plan to visualize the eradication of the lesion from beginning to end. LCDs are reimbursement decisions made by a Medicare administrative contractor, or MAC, regarding whether a particular medical service is considered reasonable and necessary, as such, whether it's covered under Medicare within the contractor's geographic jurisdiction. The question arose as to the frequency for which the ultrasound feature should be used. In mid-May, a proposed LCD to limit reimbursement for the use of ultrasound imaging prior to treating skin cancer was made public. It's important to note that in treating other forms of cancer, imaging modalities such as MRI, CT, PET, mass spectrometry, or Nuclear, they use ultrasound or other imaging devices for every fraction of treatment. With the SRT100 vision, Census innovated and introduced the same approach for treating non-melanoma skin cancer. This proposed LCD came out of nowhere. Up to that point in Q2, we were on track to surpass expectations, yet we found our market at a pause until there's clarification, which we expect soon. We are making considerable investments of time and money to lobby CMS with information and facts supporting the value of ultrasound. With this initiative, we are in lockstep with our major customer as we work together to help the -of-be understand the importance of high-frequency ultrasound in treating non-melanoma skin cancer. To date, we believe that our actions are gaining traction and understanding among those in authority and their influencers. I want to be crystal clear that our technology in treating skin cancer with SRT is not in question, but rather the frequency for which ultrasound is being used during the treatment protocols is the subject of the LCD. On the other hand, just a few weeks ago, Medicare proposed a physician fee schedule that would significantly increase reimbursement for the delivery of a code of SRT. Pivoting now to a review of operations, the Census team made meaningful progress during the second quarter. We delivered 19 SRT systems, four of which were sold to China. These placements speak to growing international demand for non-invasive therapeutic solutions and set the stage for future expansion, which Michael will explain momentarily. During Q2, we signed five new FDA contracts and activated four sites, mostly all in the first half of the quarter. Importantly, FDA treatment volume increased by 27% over Q1. That tells us practices are getting more efficient and patients are becoming more aware of SRT as a preferred treatment option. We also broadened our U.S. commercial footprint with the appointment of Radiation Oncology Systems as our primary distribution partner for the hospital-based oncology segment. This new relationship with ROS gives us specialized coverage in radiation oncology departments and freestanding cancer treatment centers, markets that traditionally require a different approach and level of engagement. ROS brings deep expertise and long-standing customer relationships, and we believe they will help accelerate our growth and increase awareness of the clinical advantages of SRT beyond dermatology. We expect to see results this year. On the R&D front, our 510K resubmission for the Next Generation TDI platform remains under FDA review. We anticipate receiving feedback later this year, and in the meantime, we continue preparing for commercial deployment. We're also refining training protocols and exploring flexible implementation models to broaden appeal across clinical settings for multiple potential applications. We also took time to elevate awareness of skin cancer and the importance of early detection. May was Skin Cancer Awareness Month, and we collaborated with advocacy organizations and providers nationwide to promote the importance of screening and noninvasive treatment options. It's part of our broader effort to position census not just as a technology leader, but as a patient-centric solution provider in the fight against skin cancer. With our domestic execution, international progress, exciting reimbursement progress, new partnerships, and a regulatory win, Q2 was a productive quarter that we believe further positioned census for success. With that, I'll turn the call over to Michael for additional commentary. Thanks.